You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Granules India gets USFDA nod for potassium chloride capsules

Capital Market 

The US drug regulator has approved the drug maker's abbreviated new drug application (ANDA) for potassium chloride extended-release capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg).

The product is a bioequivalent to the reference listed drug product (RLD), Micro-K extended-release capsules, 8 mEq and 10 mEq, of Nesher Pharmaceuticals (USA) LLC. The product would be manufactured at the company's Hyderabad facility and it is expected to be launched shortly.

Commenting on the approval, Priyanka Chigurupati, executive director, Granules Pharmaceuticals, Inc., said: We are pleased to announce approval of Potassium Chloride Capsule product within first review cycle of 10 months from filing date. This is fourth ANDA approval in our Potassium Chloride product basket.

Potassium chloride is indicated for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states.

Potassium chloride ER capsule products had U.S. sales of approximately $43 million for the most recent twelve months ending in December 2020 according to IQVIA Health.

Granules now has a total of 37 ANDA approvals from US FDA (36 final approvals and 1 tentative approvals).

Granules India is a growing pharmaceutical manufacturing company. The company produces finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs). The company's global presence extends to over 250 customers in 60 countries through offices in India, US, and UK.

On a consolidated basis, the drug maker reported 129.30% jump in net profit to Rs 146.81 crore on a 20% rise in net sales to Rs 844.51 crore in Q3 FY21 over Q3 FY20.

The scrip fell 2.59% to Rs 342 on the BSE. In the past three months, the stock has declined by 11.23% while the benchmark Sensex has added 17.71% during the same period.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, February 17 2021. 14:37 IST